HPHA Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. In addition, the company develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. Further, it develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. The company has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia, and Antibody Drug Conjugates (ADCs). The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.…
Industry Peers
BiotechnologyKey Statistics
About Heidelberg Pharma (ETR: HPHA)
›
Heidelberg Pharma (ETR: HPHA) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 2.070 EUR on 19 November 2026, down 31.0% over 52 weeks. Its 52-week range is 1.980 EUR to 3.340 EUR: the price is 38.0% below the high and 4.5% above the low.
Its market capitalisation is 96.84M EUR.
Heidelberg Pharma reports return on equity of 387.3% and an operating margin of -352.3%.
It holds more cash than debt, a net cash position of 19.54M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 6.750 EUR is 226.1% above the current price.